John Krystal
Professor of Psychiatry
Data updated
Research Footprint
John Krystal appears in 21 tracked papers (2000–2025), most studied alongside Ketamine, Placebo and LSD, across Depressive Disorders, Major Depressive Disorder (MDD) and Healthy Volunteers.
Most-cited paper: Antidepressant effects of ketamine in depressed patients (3831 citations).
Frequent co-authors: Chadi Abdallah, Gerard Sanacora and Lauren Averill.
Background & Research
John H. Krystal, MD, is a psychiatrist and neuroscientist based at Yale School of Medicine whose work bridges psychopharmacology, neuroimaging and clinical trials. He played an early and influential role in demonstrating the rapid antidepressant effects of subanaesthetic ketamine and has led and co‑authored multiple clinical studies and trials examining ketamine and other novel agents across mood, trauma-related and personality disorders. Krystal's research agenda combines experimental medicine approaches (including placebo‑controlled trials, open‑label and dose‑escalation designs) with multimodal neuroimaging to probe mechanisms of action and biomarkers of clinical response.
Key Impact
A leading clinician-scientist who helped translate NMDA-receptor antagonism into rapid-acting antidepressant treatments and who applies neuroimaging and translational methods to understand psychedelic and dissociative pharmacology.
Collaboration Network
27 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations John Krystal is associated with.
Yale School of Medicine Center for Brain Mind Health
academicA research center within Yale School of Medicine focused on understanding the neuroscience of consciousness, mental health disorders, and the mechanisms of psychoactive substances. The Center for Brain and Mind Health bridges psychiatry and neuroscience to advance knowledge of brain-mind relationships and explore novel therapeutic approaches including psychedelic-assisted treatment at Yale.
View stakeholder →Yale University
academicIn 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
View stakeholder →